Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Addex Therapeutics ( (CH:ADXN) ) has shared an announcement.
Addex Therapeutics reported a strong start to 2025, showcasing significant progress in product development and business milestones. The company regained rights to its phase 2 mGlu2 PAM asset and entered an agreement with Sinntaxis for mGlu5 NAM in brain injury recovery. Financially, Addex reported a net loss decrease due to discontinued operations, and an increase in cash reserves, highlighting its strategic financial management.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company that develops novel small molecule allosteric modulators for neurological disorders. Its lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, and the company is also advancing a GABAB PAM program for chronic cough. Addex collaborates with Indivior on a GABAB PAM candidate for substance use disorders and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various disorders.
Average Trading Volume: 176,758
Current Market Cap: CHF11.36M
See more data about ADXN stock on TipRanks’ Stock Analysis page.